Watrium invests to become a shareholder of Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer. Its leading product is UV1, a therapeutic cancer vaccine directed against human telomerase.
Watrium’s Kristin Wilhelmsen also joins the company’s board of directors. For more information, see the Ultimovacs website.
